New year, new payment system updates. It’s time to ensure you and your team are prepared for 2018, and a good place to start is by fully grasping the impact of the 2018 Outpatient Prospective Payment System (OPPS) final rule.
Chimeric Antigen Receptor Therapy (CAR-T) is the latest breakthrough in oncology care. Simply put, it involves taking a patient’s cells, sending them to the drug manufacturer where they are re-engineered, and then infusing them back into the patient to attack the patient’s cancer. CAR-T will impact many core aspects of revenue integrity, including reimbursement.
Despite opposition from many stakeholders, a bipartisan contingent of Congress, and CMS’ own advisory panel,the agency is moving forward with its plan to drastically cut payments for drugs acquired through the 340B drug discount program, according to the 2018 OPPS final rule, released November 1.